Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60

- Foong, Yi Chao, Merlo, Daniel, Patti, Francesco, Grammond, Pierre, Amato, Maria Pia, Kalincik, Tomas, Horakova, Dana, Kubala Havrdova, Eva, Weinstock-Guttman, Bianca, Lechner Scott, Jeanette, Boz, Cavit, Sa, Maria, Gresle, Melissa, Butzkueven, H, van der Walt, A, Zhu, C, MSBASE study group,, Buzzard, Katherine, Zhong, Michael, Yeh, Wei Zhen, Jokubaitis, Vilija, Monif, Mastura, Skibina, Olga, Ozakbas, Serkan

The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

- Sharmin, Sifat, Roos, Izanne, Izquierdo, Guillermo, Eichau, Sara, Boz, Cavit, Zakaria, Magd, Onofrj, Marco, Lugaresi, Alessandra, Weinstock-Guttman, Bianca, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Simpson-Yap, Steve, Lechner-Scott, Jeannette, Amato, MP, Karabudak, R, Grand'Maison, F, Khoury, SJ, Grammond, P, Lechner-Scott, J, Buzzard, K, Skibina, O, van der Walt, A, Malpes, Charles, Butzkueven, H, Turkoglu, R, Altintas, A, Maimone, D, Kermode, A, Shalaby, N, Pesch, VV, Butler, E, Sidhom, Y, Gouider, R, Sánchez, Marina M., Mrabet, S, Gerlach, O, Soysal, A, Barnett, M, Kuhle, J, Hughes, S, Sa, MJ, Hodgkinson, S, Oreja-Guevara, C, Ampapa, R, Ozakbas, Serkan, Petersen, T, Ramo-Tello, C, Spitaleri, D, McCombe, P, Taylor, B, Prevost, J, Foschi, M, Slee, M, McGuigan, C, Laureys, G, Horakova, Dana, Hijfte, LV, de Gans, K, Solaro, C, Oh, J, Macdonell, R, Aguera-Morales, E, Singhal, B, Gray, O, Garber, J, Wijmeersch, BV, Havrdova, Eva K., Simu, M, Castillo-Trivino, T, Sanchez-Menoyo, JL, Khurana, D, Al-Asmi, A, Al-Harbi, T, Deri, N, Fragoso, Y, Lalive, PH, Sinnige, LGF, Patti, Francesco, Shaw, C, Shuey, N, Csepany, T, Sempere, AP, Moore, F, Decoo, D, Willekens, B, Gobbi, C, Massey, J, Hardy, T, Alroughani, Raed, Parratt, J, Kalincik, T